• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺癌辅助治疗中给药的时间偏倚的实际演示。

Practical demonstration of time bias with administration of adjuvant therapy in lung cancer.

机构信息

Department of Radiation Oncology, Vanderbilt University Medical Center, United States.

Department of Radiation Oncology, Vanderbilt University Medical Center, United States.

出版信息

Lung Cancer. 2021 Jul;157:75-78. doi: 10.1016/j.lungcan.2021.04.019. Epub 2021 Apr 26.

DOI:10.1016/j.lungcan.2021.04.019
PMID:33994017
Abstract

PURPOSE/BACKGROUND: Immortal time bias (ITB) can hinder appropriate interpretations of studies administering adjuvant therapies. Given the increase in National Cancer Data Base (NCDB) analyses evaluating postoperative radiation therapy (PORT) as an adjuvant therapy, we sought to practically demonstrate the effects of ITB by performing a series of simulated NCDB analyses.

METHODS

A simulated NCDB analysis was performed to examine how the reported benefit of PORT in stage III non-small cell lung cancer (NSCLC) may change with adjustment for ITB utilizing sequential land mark analysis (SLMA) and time dependent Cox (TDC) modeling.

RESULTS

On the simulation analysis of 6440 NSCLC patients, we found that the omission of PORT without ITB adjustment was associated with an increased risk of death (HR 1.17, p < 0.0001). After performing a sequential LMA, the detrmient of omitting PORT continued to decrease until it was no longer significant at 8 months, HR 1.05 (p = 0.09). With the TDC model, although still significant, the relative benefit of PORT decreased, to a HR of 1.07 (p = 0.02).

CONCLUSIONS

Immortal time bias can alter the results of survival analyses if not carefully accounted for. Adjusting for this bias is essential for accurate data interpretation and to better quantify the impact and effect size of adjuvant therapies such as PORT.

摘要

目的/背景: Immortal time bias(ITB)可能会影响辅助治疗研究的合理解读。鉴于越来越多的 National Cancer Data Base(NCDB)分析评估术后放射治疗(PORT)作为辅助治疗,我们希望通过一系列模拟 NCDB 分析来实际展示 ITB 的影响。

方法

进行了模拟 NCDB 分析,以利用序贯 landmark 分析(SLMA)和时间依赖 Cox(TDC)建模来检查在调整 ITB 后,PORT 在 III 期非小细胞肺癌(NSCLC)中的获益可能如何变化。

结果

在对 6440 例 NSCLC 患者的模拟分析中,我们发现,如果不进行 ITB 调整而省略 PORT,则与死亡风险增加相关(HR 1.17,p<0.0001)。在进行序贯 LMA 后,省略 PORT 的不利影响继续下降,直到 8 个月时不再显著,HR 为 1.05(p=0.09)。使用 TDC 模型,虽然仍然显著,但 PORT 的相对获益减少,HR 为 1.07(p=0.02)。

结论

如果不仔细考虑, Immortal time bias 可能会改变生存分析的结果。调整这种偏差对于准确的数据解释以及更准确地量化辅助治疗(如 PORT)的影响和效果大小至关重要。

相似文献

1
Practical demonstration of time bias with administration of adjuvant therapy in lung cancer.肺癌辅助治疗中给药的时间偏倚的实际演示。
Lung Cancer. 2021 Jul;157:75-78. doi: 10.1016/j.lungcan.2021.04.019. Epub 2021 Apr 26.
2
Immortal Time Bias in National Cancer Database Studies.国家癌症数据库研究中的 Immortal Time Bias。
Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):5-12. doi: 10.1016/j.ijrobp.2019.07.056. Epub 2019 Aug 9.
3
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database.术后放疗在全国肿瘤学结果数据库前瞻性研究中病理 IIIA 期(N2)非小细胞肺癌中的作用。
J Thorac Oncol. 2017 Feb;12(2):302-313. doi: 10.1016/j.jtho.2016.09.135. Epub 2016 Oct 14.
4
Improved Survival With Increased Time-To-Radiation and Sequential Chemotherapy After Surgery for pN2 Non-Small-cell Lung Cancer.手术治疗 pN2 期非小细胞肺癌后增加放疗时间和序贯化疗可提高生存率。
Clin Lung Cancer. 2018 Mar;19(2):e185-e194. doi: 10.1016/j.cllc.2017.10.011. Epub 2017 Nov 20.
5
Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base.术后放疗与N2淋巴结受累的非小细胞肺癌患者更好的生存率相关:美国国立癌症数据库分析结果
J Thorac Oncol. 2015 Mar;10(3):462-71. doi: 10.1097/JTO.0000000000000411.
6
Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy.术后放疗对全肺切除术后 IIIB 期 N2 非小细胞肺癌患者的生存有益。
BMC Cancer. 2019 May 22;19(1):478. doi: 10.1186/s12885-019-5692-3.
7
Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.完全切除术后II期或IIIA期非小细胞肺癌的辅助放疗和化疗。省级肺癌疾病部位组。
Cancer Prev Control. 1997 Dec;1(5):366-78.
8
Association Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non-Small Cell Lung Cancer.N0-N1期非小细胞肺癌术后放疗的辐射剂量与预后的关联
Am J Clin Oncol. 2018 Feb;41(2):152-158. doi: 10.1097/COC.0000000000000245.
9
Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.术后放疗对接受辅助化疗的完全切除且处于Ⅰ期、Ⅱ期或ⅢA期非小细胞肺癌患者生存的影响:辅助长春瑞滨国际协作组(ANITA)随机试验
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):695-701. doi: 10.1016/j.ijrobp.2008.01.044. Epub 2008 Apr 24.
10
Radiation Therapy-First Strategy After Surgery With or Without Adjuvant Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer.术后放化疗与单纯手术治疗 IIIA-N2 期非小细胞肺癌:放疗优先策略。
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):621-7. doi: 10.1016/j.ijrobp.2015.11.020. Epub 2015 Nov 18.

引用本文的文献

1
Immortal time bias in survival outcomes when comparing treatment with chemotherapy versus immunochemotherapy for non-small cell lung cancer.比较非小细胞肺癌化疗与免疫化疗的生存结果时的不朽时间偏倚
Transl Lung Cancer Res. 2025 Jan 24;14(1):300-302. doi: 10.21037/tlcr-24-1002. Epub 2025 Jan 21.